Inhibition of interphotoreceptor retinoid-binding protein-induced uveitis by monoclonal antibodies.
Immunization of Lewis rats with interphotoreceptor retinoid-binding protein (IRBP) resulted in development of uveoretinitis in 100% (12/12) of the animals so injected. In the present study, we attempted immunotherapy of this intraocular inflammation using the monoclonal antibodies anti-I-A and anti-I-E. The antibodies were injected 1 day before and on days 1 and 2 after IRBP sensitization, and the animals were killed 16 days later. Anti-I-A treatment inhibited the disease in 83% (10/12) of the animals, while anti-I-E antibodies resulted in inhibition of the disease in 67% (8/12) of the animals. All rats injected with preimmune IgG (control animals) developed uveoretinitis. The anti-I-A and anti-I-E antibodies exerted a specific suppressor effect on the immune response of these animals. Thus, anti-I-A and anti-I-E antibodies administered at the time of antigen priming abolished the immune function and inhibited the development of autoimmune uveitis.
Atalla
L
L
Doheny Eye Institute, Los Angeles, CA 90033.
Linker-Israeli
M
M
Pararajasegaram
G
G
Rao
N A
NA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005136:Eye Proteins; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007167:Immunotherapy; D008213:Lymphocyte Activation / Q000276:immunology; D051381:Rats; D011917:Rats, Inbred Lew; D012173:Retinitis / Q000139:chemically induced / Q000517:prevention & control / Q000628:therapy; D012177:Retinol-Binding Proteins; D013601:T-Lymphocytes / Q000276:immunology; D014605:Uveitis / Q000139:chemically induced / Q000517:prevention & control* / Q000628:therapy*; D000099214:Retinol-Binding Proteins, Interstitial
D000911:Antibodies, Monoclonal; D005136:Eye Proteins; D000949:Histocompatibility Antigens Class II; D012177:Retinol-Binding Proteins; D000099214:Retinol-Binding Proteins, Interstitial